Denver, Colorado (June 10, 2011) -- The International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated to the study of lung cancer, today announced the release of its Staging Atlas in Thoracic Oncology as a downloadable application for iPad, iPhone, Android or BlackBerry.
The app, which puts the most up-to-date TNM (tumor, node, metastasis) staging information in the hands of doctors and patients living with cancer, is available in English, French, German, Japanese, Italian, Spanish and Chinese.
The Staging Atlas was developed in collaboration with the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC). It's the first-ever site-specific guide on the TNM classification of thoracic malignancies. With its IASLC-original illustrations, beautifully rendered specifically for iPad and smartphone media, it serves as a complement to and enhancement of the AJCC and UICC staging publications.
This interactive staging tool for on-the-spot verification of the most up-to-date TNM classification variables is especially valuable to oncologists, surgeons, radiologists and scientists working in the field of thoracic oncology.
It can be ordered through IASLC's website, http://iaslc.
Appshopper (for iPad and iPhone):
BlackBerry App World:
For more information about the IASLC Staging Atlas in Thoracic Oncology applications, contact firstname.lastname@example.org.
About the IASLC:
The Denver-based International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1972, the association's membership includes more than 3,000 lung cancer specialists in 80 countries.
IASLC members promote the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and thoracic malignancies. IASLC disseminates information about lung cancer to scientists, members of the medical community and the public, and uses all available means to eliminate lung cancer as a health threat for the individual patients and throughout the world. Membership is open to any physician, health professional or scientist interested in lung cancer.
IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.
To learn more about IASLC please visit http://iaslc.